转移性去势抵抗性前列腺癌患者中[177Lu]Lu-SibuDAB的生物分布与剂量学
这项前瞻性研究纳入17例已耗尽所有可用治疗方案的进展期转移性去势抵抗性前列腺癌(mCRPC)患者,首次治疗周期注射5.3±0.5 GBq [177Lu]Lu-SibuDAB,其中16例接受序贯全身SPECT/CT及静脉血样本活度测定以进行剂量学评估。结果显示肿瘤吸收剂量系数约9.9±5.4 Gy/GBq,约为临床已批准PSMA放射性药物报道值的2倍,但肿瘤/器官吸收剂量系数比与常规PSMA放射性药物相似。作者认为需进一步开展临床研究评估[177Lu]Lu-SibuDAB的疗效与安全性。
要点
- 17例mCRPC患者注射5.3±0.5 GBq [177Lu]Lu-SibuDAB,其中16例完成剂量学评估。
- 肿瘤吸收剂量系数9.9±5.4 Gy/GBq,约为临床已批准PSMA放射性药物报道值的2倍。
- 肿瘤/肾脏、肿瘤/红骨髓、肿瘤/唾液腺吸收剂量系数比分别为6.6、102、33.1。
核心结论
- [177Lu]Lu-SibuDAB显示延长的血液循环时间,因而肿瘤吸收剂量显著增加,而肿瘤/器官吸收剂量系数比与常规PSMA放射性药物相似。
- 作者认为需进一步开展临床研究以评估[177Lu]Lu-SibuDAB的疗效与安全性。
研究设计与样本
- 前瞻性研究,纳入17例(中位年龄72岁,范围63‒83岁)进展期mCRPC且已耗尽所有可用治疗方案的患者。
- 患者首次治疗周期注射5.3±0.5 GBq(均值±标准差)[177Lu]Lu-SibuDAB。
- 其中16例患者接受序贯全身SPECT/CT及静脉血样本活度测定以进行剂量学评估。
- 在OLINDA/EXM™中计算唾液腺、肝脏、脾脏、肾脏、红骨髓及选定肿瘤病灶的吸收剂量,并与既往已建立的PSMA放射性药物已发表数值比较。
主要发现
- 肿瘤吸收剂量系数为9.9±5.4 Gy/GBq,约为临床已批准PSMA放射性药物报道值的2倍。
- 唾液腺、肝脏、脾脏、肾脏、红骨髓吸收剂量系数分别为0.5±0.2、0.2±0.05、0.2±0.1、1.8±0.6、0.1±0.04 Gy/GBq,高于[177Lu]Lu-PSMA-617和[177Lu]Lu-PSMA-I&T,但低于既往研究的长时间循环PSMA放射性药物[177Lu]Lu-PSMA-ALB-56。
- 肿瘤/肾脏、肿瘤/红骨髓、肿瘤/唾液腺吸收剂量系数比分别为6.6、102、33.1。
- 上述比值在肾脏和红骨髓方面与[177Lu]Lu-PSMA-617和[177Lu]Lu-PSMA-I&T相当,在唾液腺方面更高。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出需进一步开展临床研究以评估[177Lu]Lu-SibuDAB的疗效与安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Several prostate-specific membrane antigen (PSMA) radiopharmaceuticals have been used for the treatment of metastatic, castration-resistant prostate cancer (mCRPC). In an attempt to improve the tumour accumulation, new PSMA ligands were developed with an albumin-binding entity to enhance the blood circulation and, hence, tumour accumulation. In preclinical studies, [177Lu]Lu-SibuDAB, a radiopharmaceutical with moderate albumin-binding properties, outperformed [177Lu]Lu-PSMA-617 and [177Lu]Lu-PSMA-I&T. The aim of this study was to evaluate the dosimetry of [177Lu]Lu-SibuDAB in patients diagnosed mCRPC. METHODS: Seventeen patients (median age 72 years, range 63‒83) diagnosed with progressive disease of mCRPC were included in this prospective study after exhausting all available treatment options. They were injected with 5.3 ± 0.5 GBq (mean ± standard deviation) [177Lu]Lu-SibuDAB as a first treatment cycle. Sixteen of these patients underwent sequential whole-body SPECT/CT and activity determination in venous blood samples for dosimetry purposes. Absorbed doses to the salivary glands, liver, spleen, kidneys, and red marrow as well as selected tumour lesions were calculated in OLINDA/EXM™ and compared to published values for previously established PSMA radiopharmaceuticals. RESULTS: Absorbed dose coefficients (ADC) to tumours (9.9 ± 5.4 Gy/GBq) were about 2-fold higher than those reported for clinically approved PSMA radiopharmaceuticals. ADC to salivary glands, liver, spleen, kidneys and red marrow were higher (0.5 ± 0.2, 0.2 ± 0.05, 0.2 ± 0.1, 1.8 ± 0.6, 0.1 ± 0.04 Gy/GBq, respectively) than for [177Lu]Lu-PSMA-617 and [177Lu]Lu-PSMA-I&T, but lower than for [177Lu]Lu-PSMA-ALB-56, a previously investigated long-circulating PSMA radiopharmaceutical. The tumour-to-kidneys, tumour-to-red marrow, tumour-to-salivary glands ADC ratio were 6.6, 102, 33.1. These ratios were comparable to those of [177Lu]Lu-PSMA-617 and [177Lu]Lu-PSMA-I&T for kidneys and red-marrow, but higher for salivary glands. CONCLUSION: [177Lu]Lu-SibuDAB showed a prolonged blood circulation time and, hence, a significantly increased absorbed tumour dose, while tumour-to-organ ADC ratios were similar to conventional PSMA radiopharmaceuticals. Further clinical investigations to evaluate the efficacy and safety of [177Lu]Lu-SibuDAB are, thus, warranted.
引用
- Ritt P, Fernández R, Soza-Ried C, et al. Biodistribution and dosimetry of [177Lu]Lu-SibuDAB in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2025. PMID: 39894880. doi:10.1007/s00259-025-07102-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。